2022 World Conference on Lung Cancer (ePosters)-EP08.01-088. Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C

EP08.01-088. Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C

Back to course

Pdf Summary

This study examined the combination therapy of direct acting antivirals (DAA) and immune checkpoint inhibitors (ICIs) in patients with lung cancer and hepatitis C virus (HCV) infection. The researchers aimed to determine the safety and efficacy of this sequential approach in treating these patients. <br /><br />Five patients with advanced non-small cell lung cancer (NSCLC) and HCV infection were included in the study. The patients received DAA treatment to achieve HCV clearance before starting ICIs therapy. The viral load and hepatic function were monitored throughout the treatment. ICIs therapy was initiated after observing a significant reduction in HCV viral load. The patients were monitored for response to ICIs therapy and any immune-related adverse events. <br /><br />Results showed that all patients achieved sustained virological response (SVR) with no detectable HCV RNA after DAA treatment. None of the patients experienced a flare of viral hepatitis during the combined therapy or during ICIs treatment alone. Only one patient had a temporary increase in liver enzymes, but no serious adverse events were observed. One patient had a partial response to ICIs therapy, and the overall disease control rate was 80%.<br /><br />In conclusion, the sequential approach of DAA and ICIs therapy appeared to be safe and feasible in patients with lung cancer and active HCV infection. The combination therapy did not delay the initiation of immunotherapy and showed promising results in terms of efficacy. This treatment approach may be considered for selected patients with these conditions.

Asset Subtitle

Marco Tagliamento

Meta Tag

Speaker Marco Tagliamento

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

combination therapy

direct acting antivirals

immune checkpoint inhibitors

lung cancer

hepatitis C virus

HCV infection

safety

efficacy

sequential approach

non-small cell lung cancer